
    
      In this trial, patients with ER and or PR positive breast cancer will be separately
      randomized to have chemotherapy or chemotherapy combined with endocrine therapy according to
      their menstrual status. Letrozole for the postmenopausal women and ovarian function
      suppression for the premenopausal women. Patients with triple negative breast cancer will be
      randomized to have neoadjuvant chemotherapy combined with ovarian function suppression if she
      is premenopausal. Postermenopausal patients with triple negative breast caner will only have
      neoadjuvant chemotherapy.

      Patients with Her2 overexpression can obtain anti-Her2 target therapy. This study has been
      amended to a 1:2 ratio to control and neoadjuvant chemotherapy combination of endocrine
      therapy.
    
  